Company: CMND
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001213900-25-088566
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-17
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

Convertible Promissory Note

On September 17, 2025, Clearmind
Medicine Inc. (the “Company”) entered into securities purchase agreements (the “SPAs”), with institutional investors
(the “Holders”). Pursuant to the SPAs, the Company shall issue and sell, from time to time, convertible promissory notes (the
“Notes”), in the aggregate principal amount of up to $10,000,000 (the “Subscription Amount”). Upon the execution
of the SPAs (the “First Initial Closing”), the Holders shall purchase from the Company a Note in the aggregate principal amount
of $555,556 for a purchase price of $500,000. On the date on which the Registration Statement (as defined below) is declared effective
by the Securities and Exchange Commission (the “SEC”) (the “Second Initial Closing”), the Company shall issue
and sell additional Notes in the aggregate principal amount of $1,944,444 for a purchase price of $1,750,000. Commencing on the date that
is three months after the Second Initial Closing, the Company may request, at its sole discretion, that the Holders purchase additional
Notes in the aggregate principal amount of $2,500,000 for a purchase price of $2,250,000 during each subsequent three month period such
that the aggregate amount of such additional notes is $7,500,000 for a purchase price of $6,750,000. The Company intends to use the net
proceeds from the sale of the Notes for working capital and general corporate purposes, as well